Showing results (111-120 of 174) with videos related to

Sort By:
Pageof 18
NPJ Precision Oncology|April 10, 2026
CD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapyFengmei Song, Junfang Yang, Mingming Zhang, et al.
Frontiers in Pharmacology|December 28, 2020
Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World DataJingsong He, Donghua He, Xiaoyan Han, et al.
Frontiers in Oncology|December 6, 2021
Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome-A Wandering Road to RemissionYiyun Wang, Linqin Wang, Yifan Zeng, et al.
The American Journal of the Medical Sciences|August 10, 2013
Clinical characteristics and prognosis of nonleukemic myeloid sarcomaJingsong He, Lixia Zhu, Xiujin Ye, et al.
Zhonghua Nei Ke Za Zhi|April 25, 2015
[A clinical observation of treatment of peripheral T-cell lymphoma with L-asparaginase-containing combination chemotherapy]Guoli Yao, Wanzhuo Xie, De Zhou, et al.
Frontiers in Oncology|July 1, 2021
Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Date in ChinaXiaoyan Han, Chunxiang Jin, Gaofeng Zheng, et al.
Cancer Management and Research|June 14, 2019
Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosisYan Huang, Juan Hu, Ting Lu, et al.
Frontiers in Oncology|September 20, 2021
Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in ChinaXiaoyan Han, Chunxiang Jin, Gaofeng Zheng, et al.
Blood|May 4, 2018
Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2Meidan Ying, Xuejing Shao, Hui Jing, et al.
BMC Medicine|March 3, 2026
Anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia: a multicenter retrospective studyJinglei Yu, Fengmei Song, Mingming Zhang, et al.
Pageof 18